Survival, treatment patterns, and costs of HER2+ metastatic breast cancer patients in Ontario between 2005 to 2020.
Soo Jin SeungH SaherawalaD MoldaverS ShokarC AmmendoleaC Brezden-MasleyPublished in: Breast cancer research and treatment (2023)
The baseline characteristics and treatment patterns for patients who received HER2-TT in our study align with previously reported results. However, the mOS observed for 2L T-DM1 was shorter than that found in pivotal, clinical trial literature. As expected, anti-cancer systemic therapy costs were the main contributor to the over quarter-million dollar mean cost per patient on pert_tras in 1L.
Keyphrases
- clinical trial
- metastatic breast cancer
- end stage renal disease
- chronic kidney disease
- systematic review
- ejection fraction
- type diabetes
- randomized controlled trial
- stem cells
- metabolic syndrome
- study protocol
- quantum dots
- combination therapy
- adipose tissue
- gold nanoparticles
- cell therapy
- weight loss
- smoking cessation
- room temperature
- phase iii